Vigil Neuroscience (NASDAQ:VIGL) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Vigil Neuroscience (NASDAQ:VIGL) released its quarterly earnings results on Thursday. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08), Zacks reports.

Vigil Neuroscience Stock Performance

Shares of VIGL stock traded down $0.20 on Thursday, hitting $2.15. 27,793 shares of the company’s stock traded hands, compared to its average volume of 466,949. The stock has a market capitalization of $87.85 million, a price-to-earnings ratio of -1.03 and a beta of 1.82. The company’s fifty day simple moving average is $2.33 and its 200 day simple moving average is $2.81. Vigil Neuroscience has a one year low of $1.49 and a one year high of $6.06.

Analyst Ratings Changes

A number of brokerages have issued reports on VIGL. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Vigil Neuroscience in a research report on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a report on Tuesday, November 26th. William Blair started coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They issued an “outperform” rating on the stock. Finally, Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vigil Neuroscience currently has an average rating of “Buy” and an average price target of $19.75.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.